-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-172154 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-172154 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-172154 in Myelodysplastic Syndrome Drug Details: SL-172154 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-172154 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-172154 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-172154 in Relapsed Acute Myeloid Leukemia Drug Details: SL-172154 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-172154 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-172154 in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SL-172154 in Epithelial Ovarian Cancer Drug Details:SL-172154 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Diphtheria
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Diphtheria Drug Details: Vaccine candidate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Edaravone in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Edaravone in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Edaravone in Amyotrophic Lateral Sclerosis Drug Details:Edaravone is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosgonimeton in Lewy Body Dementia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosgonimeton in Lewy Body Dementia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fosgonimeton in Lewy Body DementiaDrug Details:Fosgonimeton is under development for the treatment...
-
Company Insights
Innovation and Patenting activity of Shattuck Labs Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shattuck Labs Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Shattuck Labs Inc – Company Profile
Shattuck Labs Inc (Shattuck) is a biotechnology company that develops bi-functional fusion proteins for the treatment of cancer and autoimmune disease. The company develops products using its proprietary agonist redirected checkpoint (ARC) platform and gamma delta T Cell engager (GADLEN) platform. Shattuck’s lead products include, SL-172154 (SIRPα-Fc-CD40L) developed for the treatment of ovarian cancer, cutaneous squamous-cell carcinoma (cSCC) and head and neck squamous cell carcinoma (HNSCC) and SL-279252 (PD1-Fc-OX40L) for advanced solid tumors and lymphoma. The company is also evaluating...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colon Cancer Pipeline Products Market Report Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss...